MedTrace Logo

Phase I Study of GSK233705 in Healthy Japanese Male Subjects

NCT00964405 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2017-08-03

No results posted yet for this study

Summary

This is a randomised, double blind, placebo-controlled, 2-parts study to investigate the safety, tolerability, and pharmacokinetics of single and repeat inhaled doses of GSK233705 from a novel dry powder device in healthy Japanese male subjects.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK233705

Inhaled Long acting muscarinic receptor antagonist

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
64 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-20
Primary Completion
2008-12-20
Completion
2008-12-20

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00964405 on ClinicalTrials.gov